CRP and benign prostatic hyperplasia: Similar to their effect on IL-8 and TNF-α, finasteride or S. malaccense demonstrated the ability to mitigate BPH-induced systemic inflammation by decreasing the serum CRP concentrations in the finasteride or test groups 1 and 2 rats.